Effects of chronic consumption of cocoa flavonoids on vascular functio

Not Applicable

Completed

• Conditions: Cardiovascular disease; Circulatory System; Cardiovascular disease, unspecified

• Registration Number: ISRCTN32888088
• Lead Sponsor: Kings College London (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2007-02-28
• Study Start: 2013-08-23
• Last Update Posted: 11 November 2019

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 16

Inclusion Criteria

Non-smoking postmenopausal women aged between 48 and 65 years

Exclusion Criteria

1. Current smokers were excluded due to confounding influences of smoking on measurement of endothelial function
2. A reported history of myocardial infarction, angina, venous thrombosis, stroke, diabetes (fasting plasma glucose > 7mmol/L) or invasive cancer in the last five years
3. Recent use of oral hypolipidaemic therapy (in the last three months)
4. Current use of antihypertensive medication
5. Those receiving drugs for regulating haemostasis but excluding aspirin or who have been exposed to any investigational agent within 30 days of the study
6. Presence of gastrointestinal disorder or use of a drug, which is likely to alter gastrointestinal motility or nutrient absorption
7. Alcohol intake exceeding a moderate intake (>28 units per week)
8. Body Mass Index between <20 or >35 kg/m2
9. Blood pressure systolic >160mm Hg or diastolic >100 mm Hg
10. Fasting blood cholesterol >7.8 mmol/l
11. Fasting plasma triacyglycerol concentrations > 3 mmol/l
12. Estimated cardiovascular risk of greater than 20% over the next 10 years using the Framingham algorithm
13. Subjects unable to tolerate chocolate products
14. Dietary supplements other than vitamin and mineral supplement or fish oil (not exceeding 0.45g long chain n-3 fatty acids/d)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<br> Blood pressure<br> The outcome measures were taken at the beginning and end of each intervention period.<br>

Secondary Outcome Measures

Name	Time	Method
Arterial stiffness, flow mediated dilatation, plasma ICAM-1, VCAM-1, C-reactive protein, P-selectin, 8-isoprostane F2 a, lipids and urinary 8-isoprostane F2